Puma Biotechnology (PBYI) Gross Profit (2017 - 2026)

Puma Biotechnology (PBYI) has 10 years of Gross Profit data on file, last reported at $34.4 million in Q1 2026.

• Quarterly Gross Profit fell 2.99% year-over-year to $34.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $169.2 million (changed 0.4% YoY) and the FY2025 annual result came in at $170.2 million, up 2.5% from the prior year.
• Gross Profit fell to $34.4 million in Q1 2026, from $52.3 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $70.8 million in Q4 2022 to a low of $33.0 million in Q1 2024.
• A 5-year average of $43.4 million and a median of $42.7 million in 2023 frame the typical range for Gross Profit.
• The widest YoY moves for Gross Profit: up 62.92% in 2022, down 49.15% in 2022.
• Tracing PBYI's Gross Profit over 5 years: stood at $70.8 million in 2022, then plunged by 32.42% to $47.9 million in 2023, then slipped by 5.64% to $45.2 million in 2024, then rose by 15.88% to $52.3 million in 2025, then slumped by 34.28% to $34.4 million in 2026.
• The last three Gross Profit figures came in at $34.4 million (Q1 2026), $52.3 million (Q4 2025), and $42.3 million (Q3 2025), per Business Quant data.